138 related articles for article (PubMed ID: 37350423)
1. Healthcare resource utilization and cost among individuals with late-onset versus adult-onset Huntington's disease: a claims‑based retrospective cohort study.
To TM; Ta JT; Patel AM; Arndorfer S; Abbass IM; Gandhy R
J Med Econ; 2023; 26(1):862-870. PubMed ID: 37350423
[TBL] [Abstract][Full Text] [Related]
2. Healthcare resource utilization and costs in individuals with Huntington's disease by disease stage in a US population.
Exuzides A; To TM; Abbass IM; Ta JT; Patel AM; Surinach A; Fuller RLM; Luo J
J Med Econ; 2022; 25(1):722-729. PubMed ID: 35608039
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization and costs among individuals with vs without Huntington disease in a US population.
To TM; Exuzides A; Abbass IM; Patel AM; Ta JT; Surinach A; Fuller RLM; Luo J
J Manag Care Spec Pharm; 2022 Nov; 28(11):1228-1239. PubMed ID: 36282937
[No Abstract] [Full Text] [Related]
4. Healthcare utilization and direct medical costs of Huntington's disease among Medicaid beneficiaries in the United States.
Patel AM; Chang E; Paydar C; Reddy SR
J Med Econ; 2023; 26(1):811-820. PubMed ID: 37285853
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and cost burden of Huntington's disease among Medicare beneficiaries in the United States.
Exuzides A; Reddy SR; Chang E; Ta JT; Patel AM; Paydar C; Yohrling GJ
J Med Econ; 2021; 24(1):1327-1336. PubMed ID: 34730477
[TBL] [Abstract][Full Text] [Related]
6. Direct health care costs associated with COVID-19 in the United States.
DeMartino JK; Swallow E; Goldschmidt D; Yang K; Viola M; Radtke T; Kirson N
J Manag Care Spec Pharm; 2022 Sep; 28(9):936-947. PubMed ID: 35722829
[No Abstract] [Full Text] [Related]
7. Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.
Sipilä JOT; Kauko T; Päivärinta M; Majamaa K
J Neurol; 2017 Oct; 264(10):2095-2100. PubMed ID: 28849405
[TBL] [Abstract][Full Text] [Related]
8. Clinical and genetic characteristics of late-onset Huntington's disease in a large European cohort.
Petracca M; Di Tella S; Solito M; Zinzi P; Lo Monaco MR; Di Lazzaro G; Calabresi P; Silveri MC; Bentivoglio AR
Eur J Neurol; 2022 Jul; 29(7):1940-1951. PubMed ID: 35357736
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Jain SS; Li SS; Xie J; Sutton MB; Fine JT; Edelberg JM; Gao W; Spertus JA; Cohen DJ
J Med Econ; 2021; 24(1):1115-1123. PubMed ID: 34493144
[TBL] [Abstract][Full Text] [Related]
10. What do we know about Late Onset Huntington's Disease?
Chaganti SS; McCusker EA; Loy CT
J Huntingtons Dis; 2017; 6(2):95-103. PubMed ID: 28671137
[TBL] [Abstract][Full Text] [Related]
11. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and economic burden of Huntington's disease: a Canadian provincial public health system perspective.
Shaw E; Mayer M; Ekwaru P; McMullen S; Graves E; Wu JW; Budd N; Maturi B; Cowling T; Mestre TA
J Med Econ; 2022; 25(1):212-219. PubMed ID: 35073826
[TBL] [Abstract][Full Text] [Related]
13. Burden of influenza in patients with cardiovascular disease who receive antiviral treatment for influenza.
Corral M; Castro RC; To TM; Arndorfer S; Wang S; Stephens J
J Med Econ; 2022; 25(1):1061-1067. PubMed ID: 35943115
[TBL] [Abstract][Full Text] [Related]
14. Matched cohort study of healthcare resource utilization and costs in young children of mothers with postpartum depression in the United States.
Moore Simas TA; Huang MY; Packnett ER; Zimmerman NM; Moynihan M; Eldar-Lissai A
J Med Econ; 2020 Feb; 23(2):174-183. PubMed ID: 31597499
[No Abstract] [Full Text] [Related]
15. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis.
Divino V; Dekoven M; Warner JH; Giuliano J; Anderson KE; Langbehn D; Lee WC
J Med Econ; 2013 Aug; 16(8):1043-50. PubMed ID: 23789925
[TBL] [Abstract][Full Text] [Related]
16. Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.
Stein EM; Bonifacio G; Latrémouille-Viau D; Shi S; Guérin A; Wu EQ; Sadek I; Cao X
J Med Econ; 2021; 24(1):234-243. PubMed ID: 33472483
[TBL] [Abstract][Full Text] [Related]
17. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
18. Late-onset Huntington disease: An Italian cohort.
Volpi E; Terenzi F; Bagnoli S; Latorraca S; Nacmias B; Sorbi S; Piacentini S; Ferrari C
J Clin Neurosci; 2021 Apr; 86():58-63. PubMed ID: 33775347
[TBL] [Abstract][Full Text] [Related]
19. Disease Burden of Huntington's Disease (HD) on People Living with HD and Care Partners in Canada.
Shaw E; Mayer M; Ekwaru P; McMullen S; Graves E; Wu JW; Budd N; Maturi B; Cowling T; Mestre TA
J Huntingtons Dis; 2022; 11(2):179-193. PubMed ID: 35342095
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington's disease: a study of linked Swedish National Registries (2002-2019).
Furby H; Moore S; Nordstroem AL; Houghton R; Lambrelli D; Graham S; Svenningsson P; Petersén Å
J Neurol; 2023 Feb; 270(2):864-876. PubMed ID: 36253622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
